Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691898 · ClinicalTrials.gov registry record · Phase 1
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
NCT01691898 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 231 participants.
The verdict
NCT01691898, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
Study Summary
This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination with obinutuzumab in participants with relapsed or refractory (r/r) follicular lymphoma (FL) and r/r diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG Obinutuzumab
- DRUG Rituximab
- DRUG Polatuzumab Vedotin
- DRUG Pinatuzumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2012-09-27 |
| Est. Completion | 2019-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691898
The ClinicalTrials.gov registry entry for NCT01691898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT01691898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01691898 about?
NCT01691898 is a clinical study titled "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)". This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination with obinutuzumab in participants with relapsed or refractory (r/r) fol...
What is the current status of trial NCT01691898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2012-09-27. Estimated completion is 2019-02-07.
What interventions are being tested in trial NCT01691898?
The interventions under investigation include: Obinutuzumab (DRUG), Rituximab (DRUG), Polatuzumab Vedotin (DRUG), Pinatuzumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT01691898?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.